| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.DIAGMICROBIO.2003.09.009 |
| P698 | PubMed publication ID | 14972378 |
| P50 | author | Daniel J. Diekema | Q43292463 |
| Michael A. Pfaller | Q62070176 | ||
| P2093 | author name string | Jones RN | |
| Messer SA | |||
| Hollis RJ | |||
| Boyken L | |||
| P433 | issue | 2 | |
| P304 | page(s) | 101-105 | |
| P577 | publication date | 2004-02-01 | |
| P1433 | published in | Diagnostic Microbiology and Infectious Disease | Q15763479 |
| P1476 | title | In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents | |
| P478 | volume | 48 |
| Q42107963 | Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing |
| Q37918556 | Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations |
| Q42846025 | Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia. |
| Q35112435 | Antifungal susceptibilities of bloodstream isolates of Candida species from nine hospitals in Korea: application of new antifungal breakpoints and relationship to antifungal usage |
| Q30981454 | Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003 |
| Q40799658 | Antifungal therapies in murine infections by Candida kefyr |
| Q44972031 | Candida dubliniensis endophthalmitis: first case in North America |
| Q44309946 | Candida guilliermondii as the aetiology of candidosis |
| Q34719843 | Candida guilliermondii fungemia in patients with hematologic malignancies |
| Q37858311 | Effect of traditional Chinese medicinal herbs on Candida spp. from patients with HIV/AIDS. |
| Q30834974 | Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. |
| Q38609418 | Evaluation of the new Micronaut-Candida system compared to the API ID32C method for yeast identification |
| Q39493315 | Hydroxyurea therapy in sickle cell anemia patients aids to maintain oral fungal colonization balance. |
| Q64230610 | Identification and Functional Testing of Novel Interacting Protein Partners for the Stress Sensors Wsc1p and Mid2p of |
| Q44356533 | Identification and differential gene expression of adhesin-like wall proteins in Candida glabrata biofilms. |
| Q44260347 | In Vitro Antifungal Activity of Dihydroxyacetone Against Causative Agents of Dermatomycosis |
| Q83303203 | In vitro activities of new and conventional antimycotics against fluconazole-susceptible and non-susceptible Brazilian Candida spp. isolates |
| Q36669593 | In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates |
| Q40668115 | In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi. |
| Q41833155 | In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods. |
| Q37598686 | In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies |
| Q38989873 | In vitro studies of the activity of dithiocarbamate organoruthenium complexes against clinically relevant fungal pathogens. |
| Q34680831 | International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003). |
| Q42112398 | Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii. |
| Q37762556 | Mechanisms of antifungal drug resistance in Candida dubliniensis |
| Q37579222 | New generation azole antifungals in clinical investigation |
| Q37608276 | New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance |
| Q44855715 | Newer antifungal agents |
| Q36491819 | Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations |
| Q86202188 | Phenotypic switching of Candida guilliermondii is associated with pseudohyphae formation and antifungal resistance |
| Q25257510 | Presumptive identification of Candida species other than C. albicans, C. krusei, and C. tropicalis with the chromogenic medium CHROMagar Candida |
| Q39795440 | Prospective observational study of candidemia in São Paulo, Brazil: incidence rate, epidemiology, and predictors of mortality. |
| Q43847211 | Protective immune responses against systemic candidiasis mediated by phage-displayed specific epitope of Candida albicans heat shock protein 90 in C57BL/6J mice |
| Q35912243 | Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. |
| Q30447051 | Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. |
| Q38796140 | Systemic Antifungal Agents: Current Status and Projected Future Developments. |
| Q42678650 | The effect of ravuconazole on the pharmacokinetics of nelfinavir in healthy male volunteers |
| Q38053851 | Treatment of Candida famata bloodstream infections: case series and review of the literature. |
| Q35832184 | Upregulation of the ERG11 gene in Candida krusei by azoles |
Search more.